BIOR Stock Price, Biora Therapeutics, Inc. Quote, Chart

Market Summary

USD0.73-0.01

Market Closed

-1.35%

BIOR Stock Price

View Fullscreen

BIOR RSI Chart

BIOR Valuation

Market Cap

26.2M

Price/Earnings (Trailing)

-0.24

Price/Sales (Trailing)

84.71

EV/EBITDA

-0.34

Price/Free Cashflow

-0.53

BIOR Price/Sales (Trailing)

BIOR Profitability

EBT Margin

-36434.10%

Return on Equity

110.67%

Return on Assets

-482.27%

Free Cashflow Yield

-187.05%

BIOR Fundamentals

BIOR Revenue

Revenue (TTM)

305.0K

Rev. Growth (Yr)

6.7K%

Rev. Growth (Qtr)

49.72%

BIOR Earnings

Earnings (TTM)

-110.9M

Earnings Growth (Yr)

75.92%

Earnings Growth (Qtr)

72.75%

Breaking Down BIOR Revenue

Last 30 days

14.1%

Last 90 days

-12.0%

Trailing 12 Months

-78.2%

How does BIOR drawdown profile look like?

BIOR Financial Health

Current Ratio

0.28

Debt/Equity

-0.19

Debt/Cashflow

-2.61

BIOR Investor Care

Shares Dilution (1Y)

202.59%

Diluted EPS (TTM)

-6.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	1.2M	828.0K	726.0K	305.0K
2021	414.0K	666.0K	918.0K	1.2M
2020	113.3M	73.3M	36.8M	162.0K
2019	132.0M	136.0M	140.0M	144.0M
2018	0	0	0	128.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biora Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 15, 2024	mohanty aditya p.	acquired	-	-	819,000	chief executive officer
Feb 15, 2024	desparbes eric	acquired	-	-	325,000	chief financial officer
Feb 15, 2024	neumann clarke	acquired	-	-	230,000	see remarks
Sep 18, 2023	athyrium opportunities iii co-invest 1 lp	acquired	-	-	9,235,280	-
Aug 15, 2023	mohanty aditya p.	acquired	-	-	559,450	chief executive officer
Aug 15, 2023	mohanty aditya p.	sold (taxes)	-370,146	3.14	-117,881	chief executive officer
Aug 15, 2023	desparbes eric	acquired	-	-	219,650	chief financial officer
Aug 15, 2023	desparbes eric	sold (taxes)	-125,669	3.14	-40,022	chief financial officer
Aug 15, 2023	neumann clarke	acquired	-	-	210,175	see remarks
Aug 15, 2023	neumann clarke	sold (taxes)	-113,615	3.14	-36,183	see remarks

Which funds bought or sold BIOR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	19,556	19,556	-%
May 16, 2024	Athyrium Capital Management, LP	unchanged	-	-2,732,440	12,022,700	16.52%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-28.91	-21,174	29,154	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-57.74	-22,812	11,979	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-0.14	-1,818	7,941	-%
May 15, 2024	Engineers Gate Manager LP	sold off	-100	-20,365	-	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-8.00	35.00	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	-2,000	6,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-18.00	-	-%

Are Funds Buying or Selling BIOR?

Are funds buying BIOR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIOR

No. of Funds

Unveiling Biora Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 02, 2024	athyrium opportunities 2020 lp	35.4%	13,696,902	SC 13D/A
Feb 14, 2024	armistice capital, llc	3.80%	1,074,895	SC 13G/A
Dec 20, 2023	athyrium opportunities 2020 lp	34.9%	11,351,996	SC 13D/A
Sep 19, 2023	athyrium opportunities 2020 lp	34.0%	8,420,158	SC 13D/A
Mar 13, 2023	athyrium opportunities 2020 lp	16.4%	1,837,286	SC 13D/A
Feb 14, 2023	armistice capital, llc	5.70%	12,989,648	SC 13G
Jan 12, 2023	athyrium opportunities 2020 lp	14.2%	1,457,870	SC 13D/A
Nov 18, 2022	athyrium opportunities 2020 lp	14.6%	36,446,714	SC 13D/A

Recent SEC filings of Biora Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 17, 2024	EFFECT	EFFECT
Apr 15, 2024	CORRESP	CORRESP
Apr 12, 2024	UPLOAD	UPLOAD
Apr 12, 2024	PRE 14A	PRE 14A
Apr 08, 2024	S-3	S-3

Biora Therapeutics, Inc. News

Latest updates

Biora Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	49.7%	542,000	362,000	182,000	2,000	8,000	14,000	80,000	104,000	107,000	435,000	182,000	463,000	167,000	106,000	8,686,000	17,266,000	16,828,000	20,476,000	18,772,000	57,230,000	47,507,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-627,500	182,000	463,000	2,292,000	7,261,500	56,000	-4,569,000	-9,742,000	-4,485,000	-6,225,000	31,117,000	-
Operating Expenses	20.3%	16,058,000	13,344,000	23,321,000	14,936,000	15,546,000	13,790,000	13,967,000	14,314,000	20,015,000	20,594,000	30,743,000	36,116,000	31,631,000	16,859,500	30,722,000	26,483,000	42,784,000	44,488,000	48,616,000	45,415,000	-
S&GA Expenses	25.3%	9,053,000	7,226,000	12,774,000	8,953,000	8,356,000	8,023,000	8,147,000	8,410,000	13,457,000	12,109,000	18,517,000	22,715,000	19,958,000	-5,223,000	1,563,000	1,547,000	14,436,000	13,378,000	15,263,000	14,680,000	-
R&D Expenses	14.5%	7,005,000	6,118,000	10,547,000	5,983,000	7,190,000	5,767,000	5,820,000	5,904,000	6,558,000	8,485,000	12,226,000	13,401,000	11,673,000	11,225,000	13,043,000	12,234,000	11,240,000	14,609,000	17,080,000	16,463,000	-
EBITDA Margin	11.7%	-330	-373	-361	-168	-132	-322	-168	-179	-145	-137	-145	-195	-	-	-	-	-	-	-	-	-
Interest Expenses	49.8%	2,757,000	1,840,000	2,592,000	2,703,000	2,680,000	-	2,773,000	2,772,000	2,760,000	2,186,000	3,458,000	3,502,000	3,520,000	2,677,000	2,457,000	2,489,000	2,302,000	2,327,000	2,321,000	2,282,000	-
Income Taxes	150.5%	48,000	-95,000	1,000	4,000	-	258,500	158,000	-837,000	1,000	-122,500	-	-	7,000	165,000	-	-1,000	-37,696,000	-712,000	-	-	-
Earnings Before Taxes	73.7%	-4,141,000	-15,727,000	-73,453,000	-17,803,000	-17,441,000	-13,210,000	-14,716,000	-6,834,000	-	-75,503,500	-36,874,000	-41,400,000	-32,264,000	-35,853,500	-33,142,000	-32,723,000	-54,848,000	-51,182,000	-57,133,000	-16,409,000	-
EBT Margin	10.7%	-364	-407	-399	-207	-171	-361	-184	-193	-156	-149	-159	-214	-	-	-	-	-	-	-	-	-
Net Income	72.8%	-4,200,000	-15,413,000	-73,454,000	-17,807,000	-17,441,000	-13,722,000	-5,114,000	-5,513,000	-13,808,000	-92,874,000	-43,744,000	-78,531,000	-32,263,000	-75,528,000	-47,065,000	-52,783,000	-17,152,000	-50,476,000	-57,133,000	-16,409,000	-24,019,000
Net Income Margin	10.7%	-363	-406	-401	-177	-137	-125	-161	-188	-192	-198	-250	-350	-	-	-	-	-	-	-	-	-
Free Cashflow	9.4%	-12,511,000	-13,811,000	-11,035,000	-11,640,000	-12,116,000	-11,090,000	-9,969,000	-19,853,000	-24,297,000	-40,046,000	-43,192,000	-36,114,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-26.3%	23.00	31.00	35.00	50.00	53.00	54.00	63.00	77.00	87.00	109	98.00	120	129	154	120	186	144	102	116
Current Assets	-26.2%	14.00	19.00	19.00	34.00	37.00	38.00	46.00	60.00	75.00	99.00	93.00	114	101	126	93.00	160	-	75.00	89.00
Cash Equivalents	-28.9%	11.00	15.00	13.00	26.00	30.00	30.00	37.00	49.00	67.00	88.00	54.00	66.00	65.00	92.00	59.00	113	-	33.00	49.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00	3.00	10.00	10.00	-	11.00	8.00
Net PPE	-1.7%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	3.00	4.00	5.00	5.00	17.00	8.00	16.00	16.00	-	16.00	15.00
Goodwill	0%	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	-	-	6.00	6.00	6.00	6.00	-	6.00	6.00
Liabilities	-7.1%	123	133	153	171	158	156	160	173	180	194	275	260	254	261	180	204	195	186	153
Current Liabilities	-18.8%	51.00	63.00	70.00	38.00	25.00	23.00	27.00	41.00	47.00	62.00	103	86.00	80.00	73.00	87.00	95.00	-	100	78.00
Long Term Debt	28.2%	19.00	15.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	15.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	1.2%	-100	-101	-	-	-105	-102	-	-	-	-84.98	-	-	-	-	-	-	-	-	-
Retained Earnings	-0.4%	-955	-950	-935	-862	-844	-826	-813	-808	-802	-788	-695	-652	-573	-541	-465	-418	-	-348	-142
Additional Paid-In Capital	0.6%	874	869	836	760	758	744	735	731	728	723	538	531	467	453	424	420	-	283	124
Shares Outstanding	8.9%	30.00	28.00	23.00	13.00	12.00	9.00	7.00	7.00	7.00	7.00	4.00	3.00	2.00	-	-	-	-	-	-
Float	-	-	-	-	39.00	-	-	-	114	-	-	-	126	-	-	-	96.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	9.1%	-12,496	-13,745	-11,034	-11,620	-12,100	-11,018	-9,805	-19,639	-23,955	-40,046	-43,190	-35,686	-48,564	-70,679	-51,863	-12,316	-30,886	-45,845	-22,753	-	-
Share Based Compensation	-0.5%	1,539	1,546	10,531	2,014	2,384	2,166	2,139	1,446	2,053	2,402	3,935	3,459	2,166	1,796	2,163	2,228	2,057	592	631	-	-
Cashflow From Investing	21.7%	3,005	2,469	-1.00	-19.00	-6.00	-72.00	-164	-214	-342	211	-432	-558	-463	-2,013	-1,304	-533	-1,094	-808	-1,164	-	-
Cashflow From Financing	-63.4%	5,100	13,918	-2,848	7,630	12,081	4,516	-1,477	1,125	3,134	73,540	31,767	37,515	22,227	103,955	-834	116,017	10,584	53,645	24,762	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BIOR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 542	$ 2
Operating expenses:
Research and development	7,005	7,190
Selling, general and administrative	9,053	8,356
Total operating expenses	16,058	15,546
Loss from operations	(15,516)	(15,544)
Interest expense, net	(2,757)	(2,680)
Gain on warrant liabilities	13,915	864
Other income (expense), net	217	(81)
Loss before income taxes	(4,141)	(17,441)
Income tax expense	48	0
Net loss	$ (4,189)	$ (17,441)
Net loss per share, basic	$ (0.14)	$ (1.59)
Net loss per share, diluted	$ (0.14)	$ (1.59)
Weighted average shares outstanding, basic	29,296,767	10,970,583
Weighted average shares outstanding, diluted	29,296,767	10,970,583

BIOR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash, cash equivalents and restricted cash	$ 10,820	$ 15,211
Income tax receivable	822	830
Prepaid expenses and other current assets	2,429	3,030
Total current assets	14,071	19,071
Property and equipment, net	1,136	1,156
Right-of-use assets	1,418	1,614
Other assets	293	3,302
Goodwill	6,072	6,072
Total assets	22,990	31,215
Current liabilities:
Accounts payable	4,936	2,843
Accrued expenses and other current liabilities	16,984	17,319
Warrant liabilities	27,208	40,834
Related party senior secured convertible notes, current portion	1,976	1,976
Total current liabilities	51,104	62,972
Convertible notes, net of unamortized discount of $103 and $259 as of March 31,2024 and December 31, 2023, respectively	4,497	9,966
Senior secured convertible notes, net of unamortized discount of $ 13,992 and $11,066 as of March 31, 2024 and December 31, 2023, respectively (Note 6)	18,709	14,591
Related party senior secured convertible notes net of unamortized discount of $7,058 and $7,951 as of March 31, 2024 and December 31, 2023, respectively (including future interest of $9,747 and $9,747 as of March 31, 2024 and December 31, 2023, respectively) (Note 6)	20,072	19,179
Derivative liabilities	26,210	22,899
Other long-term liabilities	2,583	3,029
Total liabilities	123,175	132,636
Commitments and contingencies (Note 8)
Stockholders' deficit:
Common stock - $0.001 par value. 164,000,000 shares authorized;31,166,719 and 28,574,918 shares issued as of March 31, 2024 and December 31, 2023, repectively; 30,429,295 and 27,837,563 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	28	25
Additional paid-in capital	874,013	868,591
Accumulated deficit	(955,147)	(950,958)
Treasury stock - at cost; 737,424 and 737,355 shares as of March 31, 2024 and December 31, 2023, respectively	(19,079)	(19,079)
Total stockholders' deficit	(100,185)	(101,421)
Total liabilities and stockholders' deficit	$ 22,990	$ 31,215

About Biora Therapeutics, Inc.

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

CEO	Mr. Aditya P. Mohanty M.B.A.
WEBSITE	bioratherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	54

Biora Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Biora Therapeutics, Inc.? What does BIOR stand for in stocks?

BIOR is the stock ticker symbol of Biora Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biora Therapeutics, Inc. (BIOR)?

As of Fri May 17 2024, market cap of Biora Therapeutics, Inc. is 26.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIOR stock?

You can check BIOR's fair value in chart for subscribers.

What is the fair value of BIOR stock?

You can check BIOR's fair value in chart for subscribers. The fair value of Biora Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biora Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biora Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BIOR is over valued or under valued. Whether Biora Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Biora Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIOR.

What is Biora Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BIOR's PE ratio (Price to Earnings) is -0.24 and Price to Sales (PS) ratio is 84.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIOR PE ratio will change depending on the future growth rate expectations of investors.